Catalytic Activity of Three Variants (Ile, Leu, and Thr) at Amino Acid Residue 359 in Human CYP2C9 Gene and Simultaneous Detection Using Single-Strand Conformation Polymorphism Analysis
- 1 June 2000
- journal article
- case report
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 22 (3) , 237-244
- https://doi.org/10.1097/00007691-200006000-00001
Abstract
This study evaluated the catalytic activity of three variants (Ile, Leu, and Thr) at codon 359 of CYP2C9 enzymes expressed in a yeast cDNA expression system, and then established single-strand conformation polymorphism (PCR-SSCP) analysis for simultaneous detection as a screening method. Diclofenac was used for the in vitro experiment, and its hydroxy metabolite (4´-hydroxydiclofenac) was measured by HPLC. To discuss the in vivo effect of the Thr359 variant on the pharmacokinetics of phenytoin, a case report is presented. The efficiency of the SSCP method was evaluated by analyzing DNA samples from a homozygote for Ile359 and a heterozygote for Leu359 or Thr359. To evaluate the interaction between the P450 level and reductase activity, two batches of the Thr359 variant with a different P450:reductase activity ratio (1:4.0 and 1:1.4) were used. The in vitro study revealed that recombinant Ile359, Leu359, and Thr359 (2 batches) possessed a mean Km of 2.0, 16.5 and (3.8 and 2.9) μmol and Vmax of 12.4, 17.9 and (4.4 and 5.1) nmol/min/nmol P450, respectively. Although the magnitude of the change in catalytic efficiency for the Thr359 variant was close to that of the Leu359 variant, the effect of the two variants on diclofenac 4´-hydroxylation appears to be different because Leu359 variant was associated with a high Km, and Thr359 with a low Vmax. No significant differences in the kinetic data were observed between the two Thr359 enzymes, suggesting that low reductase activity in the Thr359 enzyme was not a major determinant in the present in vitro experiment. Estimated pharmacokinetic parameters of phenytoin obtained by the Bayesian method in an epileptic patient who was a heterozygote carrier for Thr359 variant were: Km = 6.45 μg/mL, Vmax = 5.77 mg/kg/d, and Vmax/Km = 0.89 L/kg/day. The Vmax/Km value in this patient was similar to the population mean value (0.90 L/kg/day) in Japanese heterozygotes for the Leu359 variant. Results for PCR-SSCP were in complete agreement with those obtained using established methods. Thus, the PCR-SSCP approach is useful for identifying these three variants of the CYP2C9 gene.Keywords
This publication has 27 references indexed in Scilit:
- Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locusPharmacogenetics, 2000
- The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population PharmacokineticsEpilepsia, 1998
- Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypesPharmacogenetics, 1998
- Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese PopulationTherapeutic Drug Monitoring, 1998
- Genetic analysis of the human cytochrome P450 CYP2C9 locusPharmacogenetics, 1996
- Allelic Variants of Human Cytochrome P450 2C9: Baculovirus-Mediated Expression, Purification, Structural Characterization, Substrate Stereoselectivity, and Prochiral Selectivity of the Wild-Type and I359L Mutant FormsArchives of Biochemistry and Biophysics, 1996
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996
- Detection of CYP2C9 polymorphism based on the polymerase chain reaction in ChinesePharmacogenetics, 1995
- Biochemistry and molecular biology of the human CYP2C subfamilyPharmacogenetics, 1994
- PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA.Genome Research, 1991